Sickness; COVID-19; This spontaneous case was reported by a consumer and describes the occurrence of ILLNESS (Sickness) and COVID-19 (COVID-19) in a 39-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.    Co-suspect products included non-company products ADALIMUMAB (HUMIRA) for Ankylosing spondylitis and SECUKINUMAB (COSENTYX) for an unknown indication.    Concurrent medical conditions included Ankylosing spondylitis.   On 01-Mar-2020, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 01-Apr-2020, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose and SECUKINUMAB (COSENTYX) (unknown route) at an unspecified dose. On an unknown date, the patient experienced ILLNESS (Sickness) and COVID-19 (COVID-19). At the time of the report, ILLNESS (Sickness) and COVID-19 (COVID-19) outcome was unknown.            No concomitant medication was reported.  The reporter's causality for the events sick and COVID for suspect Humira and Cosentyx were not reported.  It was unknown if patient was enrolled in a COVID-19 Vaccine Trial.   Primary reporter did not have the lot number information, because the packaging was discarded.  No treatment medication was reported.  Company Comment: This spontaneous case concerns a 39-year-old, male patient with history of co-suspect administration of Humira (adalimumab) for Ankylosing Spondylitis and Cosentyx (secukinumab) for an unknown indication, who experienced the unexpected, non-serious of COVID-19 and an unexpected, non-serious event. The events occurred unknown number of days after receiving Humira, unknown number of days after receiving Cosentyx, and unknown number of days after receiving the first dose of the mRNA-1273 vaccine. Of note, the administration dates of Humira and Cosentyx were not reported while the event onset dates were not provided, hence, the onset latency could not be assessed. It was reported that the patient experienced sickness and COVID-19. No symptoms were reported. The clinical course and treatment information were not provided. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report. Sender's Comments: This spontaneous case concerns a 39-year-old, male patient with history of co-suspect administration of Humira (adalimumab) for Ankylosing Spondylitis and Cosentyx (secukinumab) for an unknown indication, who experienced the unexpected, non-serious of COVID-19 and an unexpected, non-serious event. The events occurred unknown number of days after receiving Humira, unknown number of days after receiving Cosentyx, and unknown number of days after receiving the first dose of the mRNA-1273 vaccine. Of note, the administration dates of Humira and Cosentyx were not reported while the event onset dates were not provided, hence, the onset latency could not be assessed. It was reported that the patient experienced sickness and COVID-19. No symptoms were reported. The clinical course and treatment information were not provided. The benefit-risk relationship of the mRNA-1273 vaccine is not affected by this report.